StockpollyBeta
Get App
Popularity #4,254
TIVC · NASDAQ · Medical - Specialties

Tivic Health Systems (TIVC)

Develops TLR5 immunotherapies and biomanufacturing services for radiation and oncology uses.

$0.2577
At close−0.03 (−10.46%)
No recent trading data

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000000
Cost of revenue000000000000
Gross profit000000000000
222111222266
Research & development000000011123
221111111144
Selling & marketing011000000−100
General & administrative111111111240
Other expenses000000000000
Operating income−2−2−1−1−1−2−2−2−2−2−6−6
0000000000−1−1
Interest income000000000000
Interest expense000000000011
Other non-operating income000000000000
Income before tax−2−2−1−1−1−1−2−2−3−2−6−7
Net income from continuing operations−2−2−1−1−1−1−2−2−3−2−6−7
Discontinued operations000000000000
Other adjustments000000000−100
Net income−2−2−1−1−1−1−2−2−3−3−6−7
EPS, basic−$25.15−$25.88−$17.15−$5.37−$3.93−$3.20−$2.52−$2.19−$1.97−$0.90−$2.23−$2.10
EPS, diluted−$25.15−$25.88−$17.15−$5.37−$3.93−$3.20−$2.52−$2.19−$1.97−$0.90−$2.23−$2.10
Weighted average shares, basic000—00111033
Weighted average shares, diluted000—00111033
EBITDA−2−2−1−1−1−1−2−2−3−2−5−6
Depreciation & amortization000000000000
EBIT−2−2−1−1−1−2−2−2−3−2−6−6